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Abstract
Background: C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal
nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients,
may undergo extravascular hemolysis reducing clinical benefits. Despite the uniform deficiency of CD55 and of CD59,
there are always two distinct populations of PNH RBCs, with (C3+) and without (C3−) C3 binding.
Methods: To investigate this paradox, the phenomenon has been modeled in vitro by incubating RBCs from
eculizumab untreated PNH patients with compatible sera containing eculizumab, and by assessing the C3
binding after activation of complement alternative pathway.
Results: When RBCs from untreated patients were exposed in vitro to activated complement in the context
of C5-blockade, there was the prompt appearance of a distinct C3+ PNH RBC population whose size increased with time
and also with the rate of complement activation. Eventually, all PNH RBCs become C3+ to the same extent, without
differences between old and young (reticulocytes) PNH RBCs.
Conclusions: This study indicates that the distinct (C3+ and C3−) PNH RBC populations are not intrinsically different;
rather, they result from a stochastic all-or-nothing phenomenon linked to the time-dependent cumulative probability of
each individual PNH red cell to be exposed to levels of complement activation able to trigger C3 binding. These findings
may envision novel approaches to reduce C3 opsonization and the subsequent extravascular hemolysis in PNH patients
on eculizumab.
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Background
Paroxysmal nocturnal hemoglobinuria (PNH) is an ac-
quired disorder of hematopoiesis characterized by a
somatic mutation in the PIGA gene that prevents or im-
pairs the synthesis of glycosylphosphatidylinositol (GPI)
anchors [1, 2]. The deficiency on red blood cells (RBCs)
of GPI-anchored proteins [3, 4], including the comple-
ment regulators CD55 [5, 6] and CD59 [7], results in
chronic intravascular hemolysis with recurrent exacerba-
tions, anemia, smooth muscle cell dystonia, and high
risk of thrombosis [4, 8–10].
The blockade of terminal complement pathway by eculi-
zumab [11], a monoclonal antibody (moAb) against com-
plement component 5 (C5), abrogates intravascular
hemolysis with the consequent normalization of lactate de-
hydrogenase (LDH) levels in almost all patients suffering
from PNH. This treatment has proven to be safe and clin-
ically effective in hemolytic PNH patients [12–14], except
those in which bone marrow failure is the major cause of
anemia [15, 16].
The persistence (or the recurrence) of intravascular
hemolysis is observed only in few conditions: (i) Japa-
nese patients carrying a rare polymorphism of C5 [17],
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(ii) patients with an increased eculizumab turnover re-
quiring extra-dosage (pharmacokinetic breakthrough)
[18], and (iii) patients who occasionally experience tran-
sient episodes of intravascular hemolysis because of
massive complement activation during infections or in-
flammatory disorders (pharmacodynamic breakthrough)
[18–21]. Despite these small and infrequent limits, the
treatment with eculizumab has radically changed the
natural history of PNH since in most patients it reduces
anemia [12, 13] and thrombosis [22], and improves qual-
ity of life and survival [14].
However, the abrogation of intravascular hemolysis is
not the only relevant change in PNH pathophysiology
associated with eculizumab treatment. In fact, at vari-
ance with PNH patients not treated with eculizumab, a
population of GPI-negative (PNH) RBCs bound with
fragment of complement component 3 (C3) appears in
almost all patients on eculizumab [23] and, in some pa-
tients, also the less-sensitive direct antiglobulin test may
turn positive [24]. The PNH RBCs bound with C3 be-
come apparent because PNH RBCs, spared from
hemolysis by the blockade of the terminal complement
cascade, remain unable to control the early steps of the
ongoing complement activation. Eventually, these PNH
RBCs, once opsonized with complement, become poten-
tial targets of phagocytosis by macrophages, with conse-
quent variable degrees of extravascular hemolysis [23].
Accordingly, in PNH patients on eculizumab, the extent
of C3 binding correlates with reticulocyte count, the in
vivo half-life of 51Cr-labeled RBCs is reduced and there
is an excess of spleen and liver 51Cr uptake [23]. This
extravascular hemolysis is clinically relevant because it
can limit the efficacy of eculizumab to the point that
some patients may remain transfusion-dependent [14,
22–25]. The heterogeneity of mechanisms controlling
C3 binding and/or removal of C3+ PNH RBCs are likely
to account for the variable extent of C3 binding and of
the consequent extravascular hemolysis. Part of this vari-
ability may result from genetic diversity in genes coding
for endogenous regulators of complement: indeed, we
have recently shown that polymorphisms of complement
receptor 1 (CR1) gene are associated with the transfu-
sion need of patients on eculizumab [26].
The most intriguing biological feature of C3 binding is
that two distinct populations of PNH RBCs are always
present in patients on eculizumab, one with (C3+) and
one without (C3−) C3 binding, despite the uniform defi-
ciency of the GPI-anchored proteins on all PNH RBCs
[23]. The understanding of this phenomenon is of more
than academic importance because, depending on the
answer, one might explore different ways to overcome
the consequent clinical problems. In this paper, by re-
producing in vitro C3 binding in the presence of C5
blockade, we provide evidence suggesting a stochastic
model for the emergence of these two distinct, C3+ and
C3−, populations of PNH RBC.
Methods
Patients and samples
Peripheral blood samples were collected from 31 healthy
donors and from 31 patients with frank hemolytic PNH.
Nine of these patients were on eculizumab, 13 were not
and 9 have been studied before and on eculizumab.
Signed informed consent was obtained according to an
IRB-approved protocol. RBCs and sera were promptly
separated from freshly collected samples. RBCs were
washed three times in saline just before use. Sera were
stored at −80 °C.
In vitro complement activation
The approach we have used derives from the diagnostic
Ham test traditionally used to test the susceptibility of
PNH RBCs to complement-mediated lysis by activation
of the complement alternative pathway (CAP) [27–29].
Briefly, 2% RBC suspensions were incubated at 37 °C in
saline with 84% of pooled ABO-compatible sera from ei-
ther healthy donors (normal) or from PNH patients on
eculizumab (with eculizumab). Sera with eculizumab
were collected 1 h after infusion from PNH patients sta-
bly treated with eculizumab (900 mg each 2 weeks) and
with normal LDH during the last 3 months (in these
samples the expected concentration of eculizumab is be-
tween 200 and 500 μg/ml: [12, 30] a concentration that
is 5–14 times higher than the 35 μg/ml reported as the
minimal effective level of eculizumab [12]. In selected
experiments, eculizumab, obtained from remnants in the
infusion lines, was added (400 μg/ml).
CAP was activated by either spontaneous activation
(incubation in sealed tubes with 100% atmospheric air)
[31] or by mild acidification (HCl 0.016 M: the final pH
was between 6.8 and 6.5) [31–34]. All the procedures
were performed in sterile conditions. The hemolysis of
normal RBCs has been quantified by a direct spectro-
photometric method [35]. In both experimental models,
the lysis of RBCs from healthy donors was less than 2%.
The hemolysis of PNH RBCs has been quantified by
comparing the relative variation of the percentage of
normal RBCs (GPI-positive resistant to complement)
with that of PNH RBCs (GPI-negative sensitive to com-
plement) [36].
Flow cytometry
C3 binding was assessed with anti-C3d-neoantigen (A250,
Quidel, USA) secondary stained with polyclonal rabbit-
anti-mouse antibodies (Dako Cytomation, Denmark). In
selected experiments, RBCs were stained also with anti-
C3b (H11, Serotec), anti-iC3b (A209, Quidel), anti-C3c
(MCA2605, Serotec), anti-Bb (A227, Quidel), and the
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proper secondary polyclonal rabbit-anti-mouse antibodies
(Dako Cytomation). PNH RBCs have been identified with
anti-CD59 (Mem43, Serotec, UK). Intact and lysed (ghost)
RBCs have been identified by physical parameters as pre-
viously described [37]; in selected experiments, the iden-
tity of intact and of ghost RBCs has been confirmed by
staining with anti-Glycophorin A moAb (GA-R2, BD Bec-
ton Dickinson, NJ, USA).
Reticulocytes have been stained with the polymethine
dye (Ret Search II, Sysmex) that, upon excitation at
633 nm, emits between 650 and 670 nm. Briefly, 1 volume
of RBC suspension was mixed in 4 volumes of “Ret Search”
dilution buffer (Sysmex) and stained by adding the poly-
methine dye just before flow cytometry analysis [38].
Flow cytometry has been performed with either FACS-
Canto (BD) or Accuri C6 (BD). Fluorescent-activated cell
sorting (FACS) has been performed with FACSAria III
(BD).
Statistical analysis
Statistical analysis was performed using non-parametric
tests: Wilcoxon signed paired and Friedman rank sum
tests as suitable. Statistical significance was accepted for
any P < 0.05.
Results
Analysis of C3 fragments bound to PNH red blood cells in
patients on eculizumab
In most of the PNH patients undergoing eculizumab
treatment, there is a relative and an absolute increase of
PNH RBCs because complement blockade prevents their
complement-mediated lysis. In parallel, the percentage of
PNH RBCs with C3 binding increases progressively from
the time of starting eculizumab treatment (a representa-
tive patient in Fig. 1a), until a relatively stable plateau is
reached after 10–12 weeks: 5.8 ± 3.4% at 1 week (n = 8),
16.9 ± 13,3% at 4–5 weeks (n = 8), 20.5 ± 6.6% at 10–
Fig. 1 In vivo C3 binding on red cells of PNH patients on eculizumab. a Kinetics of C3 binding on red cells from a representative PNH patient
during eculizumab treatment. Before treatment (0 week), no red cell binds C3, whereas starting from 1 week of treatment three populations of
red cells are displayed: one population of normal red cells (CD59 + C3−) and two distinct populations of PNH (CD59-negative) red cells, one with
(C3+) and one without (C3−) fragments bound on their surface. b Characterization of C3 fragment bound to erythrocytes from PNH patient on
eculizumab. The left panel shows the normal (CD59-positive) and PNH (CD59-negative) populations (gated by the elliptic mark). The PNH (CD59-negative)
population (see gate in the left panel) has been analyzed with anti-C3d and either anti-C3b (middle panel) or anti-iC3b (left panel). SSC: side scatter
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12 weeks (n = 8). In a series of 41 PNH patients on stable
eculizumab treatment, we have previously observed 27.2
± 18.7% of C3+ PNH RBCs [23]. PNH RBCs with bound
C3 were stained by a moAb that recognizes a specific C3d
neo-epitope [39], but not by an anti-C3b (unable to bind
the C3d fragment) and an anti-iC3b (Fig. 1b); in addition,
these C3 bound PNH RBCs were not stained by anti-Bb
and anti-C3c antibodies (Additional file 1: Figure S1).
Modeling in vitro the in vivo binding of C3 to PNH red
blood cells
In order to investigate what happens in vivo in PNH pa-
tients on eculizumab, we have designed a novel experi-
mental setting [31], whereby RBCs from PNH patients
are exposed to the mild activation of complement that
mimics the in vivo spontaneous activation of CAP
known as C3 “tickover”. C3 “tickover” occurs because of
the spontaneous continuous and low-rate hydrolysis of
C3, followed by its interaction with Factor B, which
eventually leads to the formation of the initial fluid
phase C3 convertase (C3:H2OBb) [39–44].
When we incubated RBCs from a PNH patient in nor-
mal sera at 37 °C, we observed after 5 days a significant
degree of hemolysis [36]. The ghosts arising from
hemolysis were exclusively GPI-negative (ghosts of PNH
RBCs), and nearly all of them bound C3 fragments
(Additional file 1: Figure S2). In contrast, none of the intact
RBCs have bound C3 fragments confirming that we are
mimicking the continuous chronic intravascular hemolysis
[32, 37] occurring in vivo in PNH patients [8, 45].
When we repeated these experiments using sera with
eculizumab, there was almost no lysis of PNH RBCs (0–
10% at day 5) and we observed, already after 24 h, the ap-
pearance of a discrete population of C3+ PNH RBCs coex-
isting with PNH RBCs without C3 and with normal RBCs
(Fig. 2a). In addition, the size of the C3+ PNH RBC
population increased significantly with time (P < 0.04)
up to 29 ± 23% after 5 days (Fig. 2b). This parallels
exactly what happens in vivo in patients on eculizu-
mab (Fig. 1a). No C3 binding was observed with sera
that were previously heat-inactivated (data not
shown), confirming that the phenomenon was entirely
complement-mediated.
Fig. 2 Effect of spontaneous complement activation on PNH red cells. a Kinetics of C3 binding on PNH red cells from a representative PNH
patient not on eculizumab after spontaneous complement activation in presence of eculizumab. The first panel shows that no C3 binding is
present on red cells from patients not on eculizumab. The second panel shows that there is no C3 binding on red cells after 5 days of incubation
at 37 °C in ABO-compatible sera without eculizumab. C3 binding (C3+) appears on PNH (CD59-negative) red cells after 3 (third panel) and after 5
(fourth panel) days of incubation at 37 °C in ABO-compatible sera with eculizumab. The number in the upper right angle of each diagram indicates
the time in days (d); 0d indicates the sample analyzed before any in vitro treatment. ECU: eculizumab. b Kinetics of C3 binding on PNH red cells
from a series of PNH patients not on eculizumab after spontaneous complement activation in presence of eculizumab. The bar diagram shows
the average (+SD) proportion of PNH (CD59-negative) red cells bound with C3 in a series of patients not on eculizumab after 3 and after 5 days
of incubation at 37 °C in ABO-compatible sera with eculizumab. n: number of different patients studied at the indicated time points. Empty bars
show the experiments without addition of MgCl2 whereas the filled bars show the experiments with the addition of MgCl2 (1.25 mM). C3 binding
on PNH red cells increased significantly along the time (Wilcoxon signed paired test: P < 0.04 for the series without MgCl2 and P < 0.05 for the
series with addition MgCl2). At both 3 and 5 days C3 binding of samples with MgCl2 was significantly higher than that of the same samples
without MgCl2: P < 0.008, Wilcoxon signed paired test
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Then we have carried out similar experiments in
which CAP was activated by acidification (as in the
Ham test) [27, 28, 32]. When RBCs from patients not
on eculizumab were incubated with acidified normal
sera, there was the lysis of almost all PNH RBCs after
2 h (Fig. 3a). When we used sera with eculizumab,
the hemolysis of PNH RBCs was largely reduced but
not completely prevented (42.6 ± 12.6% after 24 h; n
= 11). The level of this “residual” hemolysis was only
slightly and not significantly reduced by adding an ex-
cess of eculizumab (400 μg/ml) that is expected to
double its final concentration: 47.1 ± 12.0 vs. 43.0 ±
10.0% (n = 5).
In addition, when complement was activated by acidifi-
cation in the presence of eculizumab, we observed the
prompt appearance of a discrete population of C3+ PNH
RBCs within 5 min from serum acidification (5.9 ± 3.6%)
and its size increased with time up to 71 ± 17% within
24 h (Fig. 3a, b; P < 0.001). Again, no C3 binding was ob-
served with sera that were previously heat-inactivated.
With the addition of 1.25 mM MgCl2 (which is known to
optimize complement activation [46]), there was a further
significant increase of C3+ PNH RBCs in both experimen-
tal settings (Figs. 2b, 3b) and also an increase of residual
hemolysis (66.7 ± 14.7% after 24 h: n = 11).
Furthermore, when RBCs from patients on eculizu-
mab, who already had both populations of C3+ and C3−
PNH RBCs, were incubated with their own acidified
sera, nearly all the C3− PNH RBCs eventually became
C3+ (Fig. 4a, b). This held true also for the C3− RBCs
physically sorted from these patients: in fact, upon com-
plement activation, also these sorted C3− PNH RBCs be-
came C3+ (Fig. 4c).
C3 binding to young (reticulocytes) and to mature PNH
red blood cells
Since in vivo not all PNH RBCs are bound with C3, one
may surmise that this could be due to intrinsic differ-
ence between the PNH RBCs that become C3+ and
those that remain C3−. For instance, it could be that
young RBCs have some extra mechanism for comple-
ment regulation, which would inhibit C3 binding and
might be lost with aging: i.e., the surface density of
glycophorin A [47], CD44, CD147 [48], and CR1 [49]
decreases with RBC aging. In order to test this hy-
pothesis, we have compared the proportion of C3+
cells among young (reticulocytes) and mature (non-re-
ticulocytes) PNH RBCs. In samples obtained ex vivo
from patients on eculizumab (n = 18), the proportion
of C3+ PNH RBCs was much lower in reticulocytes
Fig. 3 Effect of complement activation by mild acidification on PNH red cells. a Kinetics of C3 binding on PNH red cells from a representative
untreated PNH patient after complement activation in vitro by mild acidification in presence of eculizumab. Red cells from a patient not on
eculizumab incubated with acidified ABO-compatible sera without eculizumab show almost complete lysis of PNH (CD59-negative) red cells by
2 h: compare the first panel (0 h: before any acidification) and the second panel (2 h, no ECU). C3 binding (C3+) on PNH (CD59-negative) red cells
is shown before (time 0) and after 5 min, 2 h and 24 h from complement activation in ABO-compatible sera with eculizumab. b Kinetics of C3
binding on PNH red cells from a series of PNH patients not on eculizumab after complement activation in vitro by mild acidification in presence
of eculizumab. The line diagram shows the average (+SD) proportion of PNH (CD59-negative) red cells bound with C3 in a series of untreated
patients at different time points (from 5 min to 24 h) since complement activation in ABO-compatible sera with eculizumab (continuous line
without MgCl2; dotted line with 1.25 mM MgCl2). n: number of different patients studied at the indicated time points. C3 binding on PNH red cells
increased significantly along the time (Friedman rank sum test: P < 0.001 for both series with and without MgCl2). At any time C3 binding of
samples with MgCl2 was significantly higher than that of the same samples without MgCl2 (Wilcoxon signed paired test: P < 0.03 at 5 min and
1 h; P < 0.005 at 30 min and 2, 6, and 24 h)
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than in non-reticulocytes (10.5% vs. 27.7%: P < 0.0025.
Fig. 5a). Reticulocytes mature into RBCs within few
hours also in vitro [50]; thus, we have studied C3
binding only after complement activation by serum
acidification. In apparent contrast with what we have
observed in vivo in patients on eculizumab, in un-
treated PNH patients (n = 14) a similar proportion of
C3+ PNH RBCs was observed among both reticu-
locytes and non-reticulocytes (Fig. 5b) after in vitro
incubation with acidified sera with eculizumab (Fig. 5c:
45.6 vs. 37.1%).
We have obtained direct confirmation of this sce-
nario in 6 patients, which were tested in vitro before
starting eculizumab (C3+ PNH reticulocytes and non-
reticulocytes were 59 ± 21% and 53 ± 25%, respect-
ively), and re-tested in vivo after 4–8 months of
eculizumab treatment (C3+ PNH reticulocytes and
non-reticulocytes were 8 ± 5% and 23 ± 15%, respect-
ively). In all these experiments, C3 binding has never
been observed on non-PNH (GPI-positive) reticulo-
cytes (data not shown).
Discussion
The binding of C3 fragments to RBCs, characteristic of
various autoimmune hemolytic anemias, had never been
found in PNH and it has emerged as a novel phenomenon
in PNH patients on eculizumab [23, 24, 51]. It is possible
to visualize that in the absence of eculizumab no C3+
RBCs are seen because, once C3 is activated on the surface
of PNH RBCs, they will promptly undergo hemolysis. In
contrast, when C5 is blocked by eculizumab, PNH RBCs
with bound C3 survive because they are no longer lysed
by the terminal complement pathway; however, there will
be now a “new” steady state in which part of these C3-
opsonized RBCs are removed by macrophages, likely via
interaction with the complement receptor 3 [52] produ-
cing the extravascular hemolysis [23].
This “new” steady state does not detract from the
clinical benefit arising from the abrogation of intra-
vascular hemolysis. However, this observation ac-
counts for the fact that only a minority of PNH
patients on eculizumab normalizes their hemoglobin
level, and in some patients, residual anemia may even
Fig. 4 Effect of complement activation by mild acidification on PNH red cells from patients on eculizumab. a C3 binding on PNH red cells from a
representative PNH patient on eculizumab after complement activation in vitro by mild acidification in presence of eculizumab. This experiment
shows the C3 binding (C3+) on PNH (CD59-negative) red cells before (left panel) and after 6 h (right panel) from complement activation in vitro.
The number in the upper right angle of each diagram indicates the time in hours (h); 0 h indicates the sample analyzed before complement
activation in vitro. b Kinetics of C3 binding on PNH red cells from a series of PNH patients on eculizumab after complement activation in vitro by
mild acidification in presence of eculizumab. The line diagram shows the average (+SD) proportion of C3-negative PNH red cells that became
bound with C3 in a series of eculizumab-treated patients at different time points (from 1 to 24 h) since complement activation in their own sera
(continuous line without MgCl2; dotted line with 1.25 mM MgCl2). In this 7 patients, the percentage PNH red cells that in vivo were already bound
with C3 was 30.3 ± 24.5%. n: number of different patients studied at the indicated time points. c Effect of in vitro complement activation on C3−
PNH red cells from patients on eculizumab. RBCs without C3 binding have been sorted by FACS from a patient on eculizumab and subjected to
complement activation in the presence of eculizumab. Analysis of RBC with anti-CD59 and anti-C3d: just after sample drawing (left panel); after
FACS sorting of C3− RBC (middle panel); sorted C3− RBC after 2 h from complement activation in presence of eculizumab (right panel). HCl: serum
acidification. ECU: eculizumab
Sica et al. Journal of Hematology & Oncology  (2017) 10:126 Page 6 of 10
require red blood cell transfusions [14, 15, 20, 23, 24]. For
these patients there are not yet standard treatments: ste-
roids have been proven to be ineffective [51]; splenectomy
[53] or splenic artery embolization [54, 55] may be effect-
ive but raise concerns about infection and thrombosis sus-
ceptibility [15].
We have effectively reproduced in vitro the phenomenon
of C3 binding: in fact, in vitro complement activation in the
context of C5 blockade generates a distinct population of
C3+ PNH RBCs which co-exists with C3− PNH RBCs. It is
intriguing that spontaneous complement activation in vitro,
a condition that may mimic the chronic low level of com-
plement activation present in vivo, results in the same order
of C3 binding we have previously observed in vivo in PNH
patients (n = 41) on eculizumab: 29 vs. 27% [23].
In addition, this mild spontaneous complement activa-
tion is almost unable to lyse PNH RBCs (less than 10%
after 5 days), whereas serum acidification results in a
non-negligible hemolysis of PNH RBCs (~42% after
24 h) that is not prevented by an excess of eculizumab.
This is because serum acidification forces a level of com-
plement activation in excess of what happens in vivo in
the steady state [37, 56] and that might be similar to the
massive complement activation present during infection
or inflammation. This may explain the hemolytic crisis
observed in vivo in PNH patients on eculizumab in these
specific clinical circumstances, providing evidence for a
“pharmacodynamic breakthrough” [57]. Our observa-
tions [31, 58] are in keeping with the recent finding that
strong complement activation overrides C5 inhibition by
eculizumab possibly due to the generation of high dens-
ity C3 products on the RBC surface [59].
In any event, the most singular feature of C3 binding
in PNH patients on eculizumab is that, despite all PNH
RBCs are uniformly lacking GPI-anchored proteins,
there are always two distinct PNH RBC populations with
or without C3 binding. This is different from other con-
ditions, such as the paradigmatic cold agglutinin disease
[60], in which C3 binding is present on all RBCs. Thus,
C3 binding in PNH patients on eculizumab emerges as a
unique phenomenon with surprising features.
In principle, these two distinct populations might arise
from (a) their different ability to bind C3 or (b) from a sto-
chastic effect. However, when C5 is blocked by eculizu-
mab, there was the prompt appearance of a discrete
population of C3+ PNH RBCs whose size increased not
only with time but also with the level of complement acti-
vation. In fact, in vitro the proportion of C3+ PNH RBCs
after mild spontaneous complement activation (Fig. 2b)
was smaller than after more intense complement activa-
tion by acidification (Fig. 3b). Moreover, in vitro, at vari-
ance with in vivo observations, eventually all PNH RBCs
become C3+. This holds true also for C3− PNH RBCs
from patients on eculizumab that, in vitro, become all C3
+, regardless of the size of C3+ PNH RBCs population in
vivo (Fig. 4b). Finally, young RBCs are not selectively pro-
tected from C3 binding, in fact in vitro a very similar pro-
portion of young (reticulocytes) and mature (non-
reticulocytes) PNH RBCs become C3+ (Fig. 5b, c).
Altogether, these results indicate that the C3+ and the
C3− PNH RBCs are not intrinsically different: any PNH
RBCs, when exposed to complement activation in the
context of C5 blockade, may bind C3 to the same extent.
Thus, C3 binding is not a prerogative of a discrete subset
of PNH RBCs. In addition, the prompt appearance, within
5 min from serum acidification (Fig. 3a), of two distinct
populations of PNH RBCs (with and without C3) suggests
that C3 binding is an all-or-nothing phenomenon in which
a detectable level of C3 fragments stably bound to PNH
Fig. 5 C3 binding on young (reticulocytes) and mature (non-
reticulocytes) PNH red cells in the presence of eculizumab in vivo
and in vitro. Analysis of PNH (CD59-negative) red cells for
reticulocyte staining (polymethine dye) and C3 binding in a
representative patient whose red cells has been studied both a in
vivo (after 6 months of eculizumab treatment: left panel) and b in
vitro (before starting eculizumab: right panel). In the in vitro
experiment, red cells have been incubated for 2 h with acidified
ABO-compatible sera from patients on eculizumab without MgCl2
addition. Serum acidification has not induced any C3 binding to
non-PNH red cells neither with nor without eculizumab (data not
shown). c The bar diagram shows the average (+SD) proportion of
young (reticulocytes: RET, filled bars) and mature (non-reticulocytes:
no-RET, empty bars) PNH (CD59-negative) red cells bound with C3 in
patients studied during (from 3 to 36 months from the start)
eculizumab treatment (on the left: eculizumab in vivo) and in
patients not on eculizumab studied in vitro (on the right: eculizumab
in vitro). n: number of different patients. ECU: eculizumab
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RBCs is generated only when complement activation ex-
ceed a minimal threshold.
These findings support a stochastic model in which
the longer each individual RBC circulates, the higher the
probability to be exposed in specific districts of the
bloodstream to levels of complement activation that ex-
ceeds the threshold able to trigger C3 binding: for this
reason in patients on eculizumab in vivo, the percentage
of C3+ cells is much lower in reticulocytes (10.5%) than
in mature RBCs (27.7%).
On the other hand, this stochastic model may also sug-
gest that complement activation, rather than be always
systemic and generalized, may also occur within localized
spaces and within a limited time frame. Indeed, different
organs might harbor specific mechanisms of activation
and regulation of complement. This finely regulated
homeostasis could explain why in most complement-
mediated diseases the clinical presentations and complica-
tions are often organ specific (e.g., abdominal or central
nervous vein thrombosis in PNH, renal or ocular involve-
ment in genetically determined hemolytic-uremic syn-
drome and age-related macular degeneration) [61].
Conclusions
This in vitro study helps in understanding what happens
in vivo in PNH patients on eculizumab and it paves the
way for alternative strategies to overcome the clinical con-
sequences of C3 binding in PNH patients who already
benefit, completely or partially, from C5 blockade [34, 57].
For example, since the stochastic nature and the all-or-
nothing characteristic of this process, it is possible to
hypothesize that in the context of C5 blockade, the pre-
vention of C3 binding would not require a complete in-
hibition/full blockade of C3 convertase activity. Indeed,
even a partial inhibition of C3 convertase activity, just
below the threshold that triggers irreversible C3 binding,
might result in meaningful clinical benefit with less con-
cerns about the possible infectious risk associated with a
complete disabling of the complement pathway.
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